Author: Brenda Marie Rivers|| Date Published: March 3, 2021
The Biden administration is supporting collaboration between Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) to produce more COVID-19 vaccine doses through the Defense Production Act.
At the White House’s request, the Department of Health and Human Services has earmarked $105 million in initial funds to help Merck (NYSE: MRK) expand company facilities in order to manufacture vaccine J&J developed to treat the novel coronavirus, HHS said Tuesday.
The DPA investment covers the production of vaccine substance and fill-finish vial procedures under the management of J&J’s Janssen Pharmaceuticals business.
HHS noted the large-scale vaccine manufacturing effort seeks to address the U.S. government’s goal of having 100 million vaccine doses available by the end of June.
Merck will update facilities to support vaccine validation and qualification activities with funds to be executed through the HHS’ Biomedical Advanced Research and Development Authority.
The White House also asked the Department of Defense to support J&J in daily logistics operations.
Antenna Research Associates has appointed Jay Abendroth, a seasoned defense electronics executive, as chief growth officer to lead business development…
Precise Systems has appointed Michael “Mike” Risik as vice president of business development. The Lexington Park, Maryland-based company said Wednesday Risik will…
Aerospace and defense technology company Merlin has closed its business combination with Inflection Point Acquisition Corp. IV, a special purpose acquisition company…
Raytheon, an RTX business, has received a potential $212.1 million cost-plus-fixed-fee contract to provide operations and maintenance services for a relocatable over-the-horizon…
